Exponent announces the final close of its fifth fund, raising over €1 billion for Exponent Private Equity Partners V

Exponent, a leading European mid-market private equity firm, has announced the final close of its fifth fund, Exponent Private Equity Partners V, with £900 million in commitments (over €1 billion), 20% above its target.

Fund V attracted strong support from a globally diversified investor base, with commitments from longstanding partners and new investors across North America, Europe, the Middle East and Asia. The investor base includes pension funds, endowments, sovereign wealth funds, family offices and other leading institutional investors.

Fund V will continue Exponent’s strategy of investing in high-quality mid-market businesses. Over the past 15 years, Exponent has focused exclusively on corporate, family and founder owned businesses of scale (“primaries”), which are already established leaders in their markets. As the company’s first private equity owner, Exponent seeks to double profits through revenue-driven growth levers and has an established track record of achieving this with its portfolio companies.

Fund V has completed four investments so far: Chanelle Pharma, a European leader in generic and veterinary pharmaceuticals; Ethos Engineering, a specialist in sustainable, mission-critical data centre design; Kingsbridge Healthcare Group, the largest private healthcare provider in Northern Ireland, and the only hospital operator across both Northern Ireland and the Republic of Ireland; and Hippo Digital, a fast-growing technology consultancy focused on user-centred digital transformation.

Rede Partners is proud to have partnered with Exponent on this highly successful fundraise.